505 related articles for article (PubMed ID: 26503215)
21. Testing for urinary hyaluronate improves detection and grading of transitional cell carcinoma.
Passerotti CC; Srougi M; Bomfim AC; Martins JR; Leite KR; Dos Reis ST; Sampaio LO; Ortiz V; Dietrich CP; Nader HB
Urol Oncol; 2011; 29(6):710-5. PubMed ID: 19962919
[TBL] [Abstract][Full Text] [Related]
22. Presence of CSE1L protein in urine of patients with urinary bladder urothelial carcinomas.
Tai CJ; Liao CF; Su TC; Shen KH; Chang CC; Lin SH; Yeh CM; Shen SC; Lee WR; Chiou JF; Lin CH; Chen YC; Shih HY; Yeh KT; Jiang MC
Int J Biol Markers; 2012 Oct; 27(3):e280-4. PubMed ID: 22653741
[TBL] [Abstract][Full Text] [Related]
23. Critical analysis of the 2010 TNM classification in patients with lymph node-positive bladder cancer: influence of lymph node disease burden.
Pedrosa JA; Kaimakliotis HZ; Monn MF; Cary KC; Masterson TA; Rice KR; Foster RS; Bihrle R; Koch MO; Cheng L
Urol Oncol; 2014 Oct; 32(7):1003-9. PubMed ID: 25027685
[TBL] [Abstract][Full Text] [Related]
24. The prognostic value of P-cadherin in non-muscle-invasive bladder cancer.
Wang P; Lin SL; Zhang LH; Li Z; Liu Q; Gao JX; Liu DM; Bo JJ; Huang YR
Eur J Surg Oncol; 2014 Mar; 40(3):255-9. PubMed ID: 24429027
[TBL] [Abstract][Full Text] [Related]
25. HER-2 immunohistochemical expression as prognostic marker in high-grade T1 bladder cancer (T1G3).
Bongiovanni L; Arena V; Vecchio FM; Racioppi M; Bassi P; Pierconti F
Arch Ital Urol Androl; 2013 Jun; 85(2):73-7. PubMed ID: 23820653
[TBL] [Abstract][Full Text] [Related]
26. Expression of the endothelin axis in noninvasive and superficially invasive bladder cancer: relation to clinicopathologic and molecular prognostic parameters.
Eltze E; Wild PJ; Wülfing C; Zwarthoff EC; Burger M; Stoehr R; Korsching E; Hartmann A
Eur Urol; 2009 Nov; 56(5):837-45. PubMed ID: 18945538
[TBL] [Abstract][Full Text] [Related]
27. WHO 1973 grade 3 and infiltrative growth pattern proved, aberrant E-cadherin expression tends to be of predictive value for progression in a series of stage T1 high-grade bladder cancer after organ-sparing approach.
Otto W; Breyer J; Herdegen S; Eder F; Bertz S; May M; Mayr R; Lausenmeyer EM; Denzinger S; van Rhijn BW; Burger M; Hartmann A
Int Urol Nephrol; 2017 Mar; 49(3):431-437. PubMed ID: 28035618
[TBL] [Abstract][Full Text] [Related]
28. Low expression of protocadherin7 (PCDH7) is a potential prognostic biomarker for primary non-muscle invasive bladder cancer.
Lin YL; Wang YL; Fu XL; Li WP; Wang YH; Ma JG
Oncotarget; 2016 May; 7(19):28384-92. PubMed ID: 27070091
[TBL] [Abstract][Full Text] [Related]
29. Quantitative analysis of survivin mRNA expression in urine and tumor tissue of bladder cancer patients and its potential relevance for disease detection and prognosis.
Weikert S; Christoph F; Schrader M; Krause H; Miller K; Müller M
Int J Cancer; 2005 Aug; 116(1):100-4. PubMed ID: 15761870
[TBL] [Abstract][Full Text] [Related]
30. Correlations of Foxo3 and Foxo4 expressions with clinicopathological features and prognosis of bladder cancer.
Wang Y; Kang XL; Zeng FC; Xu CJ; Zhou JQ; Luo DN
Pathol Res Pract; 2017 Jul; 213(7):766-772. PubMed ID: 28554751
[TBL] [Abstract][Full Text] [Related]
31. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
[TBL] [Abstract][Full Text] [Related]
32. Direct quantitative detection for cell-free miR-155 in urine: a potential role in diagnosis and prognosis for non-muscle invasive bladder cancer.
Zhang X; Zhang Y; Liu X; Fang A; Wang J; Yang Y; Wang L; Du L; Wang C
Oncotarget; 2016 Jan; 7(3):3255-66. PubMed ID: 26657502
[TBL] [Abstract][Full Text] [Related]
33. The Impact of Tumor Diameter and Tumor Necrosis on Oncologic Outcomes in Patients With Urothelial Carcinoma of the Bladder Treated With Radical Cystectomy.
Soave A; John LM; Dahlem R; Minner S; Engel O; Schmidt S; Kluth LA; Fisch M; Rink M
Urology; 2015 Jul; 86(1):92-8. PubMed ID: 26051839
[TBL] [Abstract][Full Text] [Related]
34. A combination of p40, GATA-3 and uroplakin II shows utility in the diagnosis and prognosis of muscle-invasive urothelial carcinoma.
Leivo MZ; Elson PJ; Tacha DE; Delahunt B; Hansel DE
Pathology; 2016 Oct; 48(6):543-9. PubMed ID: 27594510
[TBL] [Abstract][Full Text] [Related]
35. Urine markers for bladder cancer surveillance: a systematic review.
Ratliff TL
J Urol; 2005 Nov; 174(5):2065-6. PubMed ID: 16217395
[No Abstract] [Full Text] [Related]
36. E-cadherin immunostaining of bladder transitional cell carcinoma, carcinoma in situ and lymph node metastases with long-term followup.
Byrne RR; Shariat SF; Brown R; Kattan MW; Morton RA JR; Wheeler TM; Lerner SP
J Urol; 2001 May; 165(5):1473-9. PubMed ID: 11342899
[TBL] [Abstract][Full Text] [Related]
37. Expression of CD147, BIGH3 and Stathmin and their potential role as diagnostic marker in patients with urothelial carcinoma of the bladder.
Bhagirath D; Abrol N; Khan R; Sharma M; Seth A; Sharma A
Clin Chim Acta; 2012 Oct; 413(19-20):1641-6. PubMed ID: 22626996
[TBL] [Abstract][Full Text] [Related]
38. Histological and immunohistochemical markers for progression prediction in transurethrally resected high-grade non-muscle invasive bladder cancer.
Kim K; Cho YM; Park BH; Lee JL; Ro JY; Go H; Shim JW
Int J Clin Exp Pathol; 2015; 8(1):743-50. PubMed ID: 25755769
[TBL] [Abstract][Full Text] [Related]
39. Osteopontin overexpression predicts poor prognosis of upper urinary tract urothelial carcinoma.
Ke HL; Chang LL; Yang SF; Lin HH; Li CC; Wu DC; Wu WJ
Urol Oncol; 2011; 29(6):703-9. PubMed ID: 20022267
[TBL] [Abstract][Full Text] [Related]
40. UBE2C cell-free RNA in urine can discriminate between bladder cancer and hematuria.
Kim WT; Jeong P; Yan C; Kim YH; Lee IS; Kang HW; Kim YJ; Lee SC; Kim SJ; Kim YT; Moon SK; Choi YH; Kim IY; Yun SJ; Kim WJ
Oncotarget; 2016 Sep; 7(36):58193-58202. PubMed ID: 27528424
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]